European Commission 3 August 2010, Commission Decision of 03/08/2010 declaring a concentration to be compatible with the common market (Case No COMP/M.5865 - TEVA / RATIOPHARM) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

Also known as

The Commission Decision 32010M5865 evaluates the acquisition of Ratiopharm by Teva Pharmaceutical Industries, determining that the concentration is compatible with the common market under Council Regulation (EC) No 139/2004. The decision highlights that the merger will create the largest generic pharmaceutical player in the EEA, significantly impacting market shares in various Member States while maintaining competition due to the fragmented nature of the generic market. The assessment concludes that the transaction does not raise significant competition concerns, given the existing competitive landscape and the parties' market positions.AI